Comparative Pharmacology
Head-to-head clinical analysis: KEFLEX versus ZINACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLEX versus ZINACEF.
KEFLEX vs ZINACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefuroxime, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours; maximum 4 g/day.
750 mg IV/IM every 8 hours; for severe infections: 1.5 g IV every 8 hours; for life-threatening infections: 1.5 g IV every 6 hours
None Documented
None Documented
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; prolonged to 2.5-3.5 hours in elderly and up to 48 hours in end-stage renal disease.
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Renal: 80-95% unchanged via glomerular filtration and tubular secretion; biliary: 5-10% excreted in feces; fecal: negligible.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic